Twitter feed
Follow us
Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations via @PricingGlobal
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, re...
globalpricinginnovations.wordpress.com
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations https://t.co/Ar1IA9H3ss
Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU
Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Video post by @PricingGlobal.
globalpricinginnovations.wordpress.com
Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing
The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA
What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI
Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
https://t.co/0DEsm7LGXc
Gene therapy for 'bubble baby' syndrome approved on NHS
Gene therapy for 'bubble baby' syndrome approved on NHS
GlaxoSmithKline’s Strimvelis is the first such treatment to be funded in the UK
lnkd.in
Season’s Greetings from GPI https://t.co/Ig1Ro3kSwl
Fanfare and optimism for UK’s Life Sciences Sector Deal
Fanfare and optimism for UK’s Life Sciences Sector Deal - Pharmaphorum
The Life Sciences sector has been chosen as the flagship for the UK’s post-Brexit industrial strategy, with an
lnkd.in
National science panel calls for aggressive steps to control drug prices
National science panel calls for aggressive steps to control drug prices - Los Angeles Times
A new report from the National Academies of Sciences, Engineering and Medicine recommends steps to make prescription drugs more affordable.
lnkd.in
Provinces reject price negotiations for Orkambi cystic fibrosis drug
/arc-anglerfish-tgam-prod-tgam.s3.amazonaws.com/public/ZJNFXJX6ZNDKZOOJWHWGSHK4K4.jpg)
Provinces reject price negotiations for Orkambi cystic fibrosis drug
Costly drug used to treat cystic fibrosis has been rejected twice for public funding as agency notes limited evidence of effectiveness
lnkd.in
FDA approves pill with sensor that digitally tracks if patients have ingested their medication https://t.co/K5Sln5WEBf #innovation #adherence
Humira becomes Boehringer’s first biosimilar approved in Europe https://t.co/zYMTIlofgH #biosimilars #access #innovation
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
Bayer is working to position Stivarga as part of a liver cancer treatment regimen, But that’s not going to work in England. At least, not yet.
lnkd.in
New research highlights countries using International Referencing Pricing for price setting #pricing #strategy
Looking forward to ISPOR Glasgow? Drop by our poster and say "Hello"
ANALYSIS OF USING IRP AS A LAUNCH PRICE SETTING MECHANISM
https://t.co/A0X2J68qTo
AZ, Incyte to test lung cancer combo in PhIII https://t.co/E9exmb6Ymq
‘Breakthrough’ tag for GSK’s multiple myeloma drug https://t.co/DnoQ7yjPzp #innovation #access
Pharmaceutical company withdraws oncology drug from Greek market
Pharmaceutical company withdraws oncology drug from Greek market
A multinational pharmaceutical company has decided to withdraw an innovative oncology medicine from the Greek market, claiming that its price has fall...
lnkd.in
https://t.co/YDlVZSC0jh
A first for NICE in the UK.....Higher Cost Effectiveness threshold applied for a rare disease …
GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
GlaxoSmithKline's gene therapy Strimvelis won the backing of U.K. cost watchdogs to treat a rare disease called ADA-SCID, or "bubble boy" syndrome.
lnkd.in
NICE approves gene therapy for rare ‘bubble baby syndrome’ #innovation #access
NICE final draft guidance recommends gene therapy for rare ‘bubble baby syndrome’
NICE approves gene therapy for rare ‘bubble baby syndrome’
www.nice.org.uk
Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations via @PricingGlobal
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, re...
globalpricinginnovations.wordpress.com
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations https://t.co/Ar1IA9H3ss
Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU
Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Video post by @PricingGlobal.
globalpricinginnovations.wordpress.com
Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing
The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA
What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI
Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
https://t.co/0DEsm7LGXc
Gene therapy for 'bubble baby' syndrome approved on NHS
Gene therapy for 'bubble baby' syndrome approved on NHS
GlaxoSmithKline’s Strimvelis is the first such treatment to be funded in the UK
lnkd.in
Season’s Greetings from GPI https://t.co/Ig1Ro3kSwl
Fanfare and optimism for UK’s Life Sciences Sector Deal
Fanfare and optimism for UK’s Life Sciences Sector Deal - Pharmaphorum
The Life Sciences sector has been chosen as the flagship for the UK’s post-Brexit industrial strategy, with an
lnkd.in
National science panel calls for aggressive steps to control drug prices
National science panel calls for aggressive steps to control drug prices - Los Angeles Times
A new report from the National Academies of Sciences, Engineering and Medicine recommends steps to make prescription drugs more affordable.
lnkd.in
Provinces reject price negotiations for Orkambi cystic fibrosis drug
Provinces reject price negotiations for Orkambi cystic fibrosis drug
Costly drug used to treat cystic fibrosis has been rejected twice for public funding as agency notes limited evidence of effectiveness
lnkd.in
FDA approves pill with sensor that digitally tracks if patients have ingested their medication https://t.co/K5Sln5WEBf #innovation #adherence
Humira becomes Boehringer’s first biosimilar approved in Europe https://t.co/zYMTIlofgH #biosimilars #access #innovation
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
Bayer is working to position Stivarga as part of a liver cancer treatment regimen, But that’s not going to work in England. At least, not yet.
lnkd.in
New research highlights countries using International Referencing Pricing for price setting #pricing #strategy
Looking forward to ISPOR Glasgow? Drop by our poster and say "Hello"
ANALYSIS OF USING IRP AS A LAUNCH PRICE SETTING MECHANISM
https://t.co/A0X2J68qTo
AZ, Incyte to test lung cancer combo in PhIII https://t.co/E9exmb6Ymq
‘Breakthrough’ tag for GSK’s multiple myeloma drug https://t.co/DnoQ7yjPzp #innovation #access
Pharmaceutical company withdraws oncology drug from Greek market
Pharmaceutical company withdraws oncology drug from Greek market
A multinational pharmaceutical company has decided to withdraw an innovative oncology medicine from the Greek market, claiming that its price has fall...
lnkd.in
https://t.co/YDlVZSC0jh
A first for NICE in the UK.....Higher Cost Effectiveness threshold applied for a rare disease …
GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
GlaxoSmithKline's gene therapy Strimvelis won the backing of U.K. cost watchdogs to treat a rare disease called ADA-SCID, or "bubble boy" syndrome.
lnkd.in
NICE approves gene therapy for rare ‘bubble baby syndrome’ #innovation #access
NICE final draft guidance recommends gene therapy for rare ‘bubble baby syndrome’
NICE approves gene therapy for rare ‘bubble baby syndrome’
www.nice.org.uk
